Literature DB >> 22037265

Radiofrequency ablation of lung cancer at Okayama University Hospital: a review of 10 years of experience.

Takao Hiraki1, Hideo Gobara, Hidefumi Mimura, Shinichi Toyooka, Hiroyasu Fujiwara, Kotaro Yasui, Yoshifumi Sano, Toshihiro Iguchi, Jun Sakurai, Nobuhisa Tajiri, Takashi Mukai, Yusuke Matsui, Susumu Kanazawa.   

Abstract

The application of radiofrequency ablation for the treatment of lung cancer by our group at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences began in June 2001, and in the present report, we review our 10-year experience with this treatment modality at Okayama University Hospital. The local efficacy of radiofrequency ablation for the treatment of lung cancer depends on tumor size and the type of electrode used, but not on tumor type. An important factor for the prevention of local failure may be the acquisition of an adequate ablative margin. The combination of embolization and radiation therapy enhances the local efficacy. Local failure may be salvaged by repeating the radiofrequency ablation, particularly in small tumors. Survival rates after radiofrequency ablation are quite promising for patients with clinical stage I non-small cell lung cancer and pulmonary metastasis from colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. The complications caused by radiofrequency ablation can be treated conservatively in the majority of cases. However, attention should be paid to rare but serious complications. This review shows that radiofrequency ablation is a promising treatment for patients with lung cancer.

Entities:  

Mesh:

Year:  2011        PMID: 22037265     DOI: 10.18926/AMO/47010

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  8 in total

Review 1.  Thermal ablation of stage I non-small cell lung carcinoma.

Authors:  Carol A Ridge; Stephen B Solomon; Raymond H Thornton
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 2.  Systemic Versus Local Therapies for Colorectal Cancer Pulmonary Metastasis: What to Choose and When?

Authors:  Tony Ibrahim; Lambros Tselikas; Charbel Yazbeck; Joseph Kattan
Journal:  J Gastrointest Cancer       Date:  2016-09

3.  Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients.

Authors:  Takuya Sato; Toshihiro Iguchi; Takao Hiraki; Hideo Gobara; Hiroyasu Fujiwara; Jun Sakurai; Yusuke Matsui; Toshiharu Mitsuhashi; Junichi Soh; Shinichi Toyooka; Susumu Kanazawa
Journal:  Jpn J Radiol       Date:  2016-11-18       Impact factor: 2.374

Review 4.  Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer.

Authors:  Takao Hiraki; Hideo Gobara; Toshihiro Iguchi; Hiroyasu Fujiwara; Yusuke Matsui; Susumu Kanazawa
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

5.  A pulmonary artery pseudoaneurysm caused by concurrent chemoradiation therapy for lung cancer.

Authors:  Jung Ho Kim; Sang Hoon Han
Journal:  Pak J Med Sci       Date:  2015 Jan-Feb       Impact factor: 1.088

6.  Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.

Authors:  Peng Yan; An-Na Tong; Xiu-Li Nie; Min-Ge Ma
Journal:  BMC Med Imaging       Date:  2021-06-07       Impact factor: 1.930

7.  Radiofrequency ablation of T1 lung carcinoma: comparison of outcomes for first primary, metachronous, and synchronous lung tumors.

Authors:  Carole A Ridge; Mikhail Silk; Elena N Petre; Joseph P Erinjeri; William Alago; Robert J Downey; Constantinos T Sofocleous; Raymond H Thornton; Stephen B Solomon
Journal:  J Vasc Interv Radiol       Date:  2014-04-02       Impact factor: 3.682

8.  A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.

Authors:  Jie Yin; Jingyin Dong; Wei Gao; Yina Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.